BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Kelun-Biotech and Harbour BioMed Ink $970 Million Licensing Deal with Windward Bio for Anti-TSLP Antibody

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (togeth...

January 13, 2025 | News

MSD’s GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the National Medical Products Administration (NMPA) of China ...

January 10, 2025 | News

Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantical...

January 10, 2025 | News

Biocytogen and Acepodia Join Forces to Advance Precision Oncology with Dual-Payload Bispecific ADCs

Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s...

January 08, 2025 | News

Dizal’s China-Origin Sunvozertinib Secures FDA Priority Review for EGFR Exon20ins NSCLC

If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with E...

January 08, 2025 | News

Alebund Pharmaceuticals Secures RMB 550 Million Series C Financing to Advance Innovative Renal Therapies

Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal di...

January 08, 2025 | News

Asieris Pharmaceuticals Partners with CDC for Investigational Use of APL-1202 in Fatal Free-Living Amoebae Infections

Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary t...

January 07, 2025 | News

Technoderma Medicines Announces Positive Phase 2a Results for TDM-180935 in Atopic Dermatitis

Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinic...

January 07, 2025 | News

WuXi Biologics Partners with Candid Therapeutics in $925M Deal to Advance Trispecific T-Cell Engagers

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced an agreemen...

January 07, 2025 | News

WuXi Biologics to Sell $500M Irish Vaccine Facility to Merck & Co. Amid U.S. Legislative Pressures

WuXi Biologics has announced plans to sell its vaccine manufacturing facility in Dundalk, Ireland, to Merck & Co. for approximately $500 million. This ...

January 06, 2025 | News

Human Metapneumovirus Sparks Concern Across Asia: India Joins Global Vigilance

The detection of Human Metapneumovirus (HMPV) in Karnataka, India, and a rising number of cases across Asia have prompted heightened vigilance among health...

January 06, 2025 | Analysis

Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the National Medical Products Administration (N...

January 06, 2025 | News

Everest Medicines Announces NEFECON® NRDL Implementation in China to Expand Access for IgAN Patients

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

January 06, 2025 | News

MicuRx’s MRX-5 Receives FDA Orphan Drug Designation for Non-Tuberculous Mycobacteria Infections

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug ...

January 02, 2025 | News

Stay Connected